Abstract
ObjectivesTo evaluate clinical response by baseline disease duration using 2-year data from the AMPLE trial.MethodsPatients were randomised to subcutaneous abatacept 125 mg weekly or adalimumab 40 mg bi-weekly, with background...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
